Image for the purpose of representation. | Photo Credit: File
The Union Health Ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, to include ‘antimicrobials’ in the definition of ‘New Drug’ under Rule 2(1)(w)(v).
Antimicrobial resistance (AMR) is a major global public health concern and the proposed amendment has been initiated in view of concerns regarding the grant of manufacturing licences for antimicrobial products without adequate regulatory scrutiny, including the requirement for studies such as bioavailability and bioequivalence and stability studies.
The proposed amendment seeks to bring antimicrobials within the regulatory framework applicable to new drugs under the New Drugs and Clinical Trials Rules, 2019. Accordingly, manufacturers would be required to obtain permission from the Central Licensing Authority before applying for a manufacturing licence from the concerned State Licensing Authority. This is expected to strengthen central regulatory oversight and help ensure the quality, safety and efficacy of antimicrobial products.
Meanwhile, the Ministry has also proposed amendments to the Drugs Rules, 1945, to introduce a separate application form (Form 19-BC) and licence form (Form 20-BC) for the sale of bulk drugs (active or inactive bulk substances), distinct from the existing licensing provisions for formulations.
At present, a common licence covers the wholesale sale of both formulations and bulk drugs. The proposed amendment seeks to establish a dedicated licensing framework for bulk drugs, enabling more focused regulatory oversight of their wholesale sale and greater accountability in the pharmaceutical supply chain.
The proposal was agreed upon by the Drugs Consultative Committee (DCC) in its 67th meeting held on November 17, 2025, and by the Drugs Technical Advisory Board (DTAB) in its 93rd meeting held on February 16, 2026.
Under the proposed framework, the licence will capture the categories of bulk drugs handled by wholesalers, including drugs covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The sale of bulk drugs will be carried out under the personal supervision of a competent person, thereby strengthening accountability in their distribution and handling.
“Upon implementation, the proposed amendment will: give better control over the sale of bulk drugs by way of wholesale, strengthen enforcement control in relation to antimicrobial resistance and the movement of NDPS drugs and require wholesalers of bulk drugs to obtain a separate license for sale.” Stakeholders and members of the public are invited to submit their objections and suggestions.
Published - November 19, 2026 04:56 pm IST
Source: The Hindu · Bindu Shajan Perappadan
At a glance
- Topic
- Politics
- Country
- 🇮🇳 IN
- Publisher language
- EN
- Added to Allnira